Objective: Our hypothesis was that patients with diabetes mellitus obtain an additional risk of death if they develop Addison's disease (AD). Design and methods: Nationwide, matched, observational cohort study cross-referencing the Swedish National Diabetes Register with Inpatient, Cancer and Cause of Death Registers in patients with diabetes (type 1 and 2) and AD and matched controls with diabetes. Clinical characteristics at baseline, overall, and cause-specific mortality were assessed. The relative risk of death was assessed using a Cox proportional hazards regression model. Results: Between January 1996 and December 2012, 226 patients with diabetes and AD were identified and matched with 1129 controls with diabetes. Median (interquartile range) follow-up was 5.9 (2.7-8.6) years. When patients with diabetes were diagnosed with AD, they had an increased frequency of diabetes complications, but both medical history of cancer and coronary heart disease did not differ compared with controls. Sixty-four of the 226 patients with diabetes and AD (28%) died, while 112 of the 1129 controls (10%) died. The estimated relative risk increase (hazard ratio) in overall mortality in the diabetes and AD group was 3.89 (95% confidence interval 2.84-5.32) compared with controls with diabetes. The most common cause of death was cardiovascular in both groups, but patients with diabetes and AD showed an increased death rate from diabetes complications, infectious diseases and unknown causes. Conclusions: Patients with the rare combination of diabetes and AD showed a markedly increased mortality and died more frequently from infections and unknown causes than patients with diabetes alone. Improved strategy for the management of this combination of metabolic disorders is needed.
Introduction
Diabetes mellitus (DM) type 1 and type 2 are established risk factors for cardiovascular disease (1) and strongly associated with increased risk of death (2) . These associations are related to glycaemic control and the presence of co-morbidities such as hypertension (3) and DM-related nephropathy (4) . For example, in patients with type 1 DM (T1DM), the risk of all-cause mortality is increased nearly 5-fold in the presence of microalbuminuria (5) .
Addison's disease (AD) or primary adrenal insufficiency is, in the Western world, most commonly due to autoimmune destruction of the adrenal cortex causing cortisol, aldosterone and androgen deficiency (6) . Patients with AD may also have other autoimmune manifestations, with approximately half of them having autoimmune thyroid disease and up to 14% also have T1DM (7) . Patients with AD and either T1DM or autoimmune thyroid disease or both are classified as having autoimmune polyendocrine syndrome type 2 (8) . Both T1DM and AD are deadly diseases unless treated with insulin and glucocorticoids respectively (9) . Patients with AD, receiving conventional replacement therapy, still have a 2-fold increased mortality risk compared with the general population (10, 11) , which is mainly due to cancer, cardiovascular diseases and infections (10) .
The combination of T1DM and AD is rare with an estimated prevalence of 20 cases per million inhabitants (7) , which may explain the paucity of outcome data in this patient group. A small study of ten patients with T1DM and AD showed different basal and meal-related insulin requirements compared with patients having only T1DM (12) . A recent study based on health insurance data showed increased risk of adrenal crisis among patients with T1DM and AD compared with patients with only AD (13) , and an epidemiological study showed that patients with AD and DM had an increased risk of death compared with patients with only AD (10) .
Having both DM (T1DM and type 2 DM (T2DM)) and AD is a complicated condition due to the complex metabolic interplay between insulin and cortisol. Our hypothesis is that mortality is increased in these patients above that seen among patients with DM alone. Using the detailed clinical information provided by the Swedish National Diabetes Register (NDR) combined with other Swedish national databases, we performed a nationwide, matched, observational study to determine the overall and cause-specific mortality in patients with DM from the time they were diagnosed with AD.
Subjects and methods

Study design
This is a nationwide, matched, observational cohort study using data from the Swedish NDR, the Swedish National Inpatient Register, the Swedish Cancer Register and the Swedish Cause of Death Register. The NDR is a quality register with a 97% nationwide coverage (14) to which detailed clinical information on adult patients with DM is reported. Each patient provides informed consent for inclusion in the register. The Swedish National Inpatient Register includes data on all inpatient admissions in Sweden from 1987 onward. The Swedish Cancer Register includes data on cancer and the Swedish Cause of Death Register includes data on causes of death. All registries are continuously validated, have a coverage of about 99% and are linked to each other by a unique personal identification code (15, 16, 17, 18) . The study was approved by the Regional Ethical Review Board in Gothenburg, Sweden.
Procedures
First, we identified patients with either T1DM or T2DM and AD in the Swedish National Inpatient Register between 1 January 1988 and 31 December 2012 (in a total population of 628 475 individuals) ( Fig. 1 ). Then, we crossmatched these patients with patients registered in the NDR having DM and AD. These patients with DM and AD in the NDR (cases) were, finally, matched to five controls with DM alone, also registered in NDR. The observation period was from 1 January 1996 (when the NDR started) to 31 December 2012. Patients were identified using the codes of the International Classification of Diseases, Ninth Revision (ICD-9) for years 1987-1996 and for ICD-10 for years 1997-2012. Codes from ICD-7 were used for cancer diagnosis in the Swedish Cancer Register. The codes used to identify DM were ICD-9 code 250 and ICD-10 codes E10-E14 and to identify patients with AD ICD-9 code 255.4 and ICD-10 codes E27.1 and/or E27.2. The search criteria for AD in the Swedish National Inpatient Register have been previously validated (10) . Patients with endogenous Cushing's syndrome and/or any disorders of the pituitary gland were excluded. Details on all ICD-9 and ICD-10 codes used in this study are presented in Supplementary  Table 1 , see section on supplementary data given at the end of this article. The period used to retrieve baseline data was between 1 year before and 2 weeks after the AD diagnosis for cases or inclusion in the study for controls.
Glycosylated haemoglobin concentrations (HbA1c) were analysed at local laboratories. Analyses of HbA1c are quality assured nationwide by regular calibration with the high-performance liquid chromatography Mono-S method, with measurements converted to mmol/mol (19) . We used the clinical classification of T1DM and T2DM, which is the diagnosis attributed to the patients by the physicians who reported them to the NDR.
Outcomes
After inclusion, all patients were monitored in the Swedish Cause of Death Register until they died or until end of cut-off on 31 December 2012. The primary outcomes were all-cause mortality and main cause of death, which is the primary cause of death as defined by a physician on the death certificate. Main causes of death, in accordance with previous studies in patients with AD (11, 20) , were categorised as death from cardiovascular disease, cancer, DM complications, acute/chronic adrenal failure, infection (including sepsis), acute/chronic renal failure, gastrointestinal disease, chronic lung disease and sudden death.
Statistical analysis
Baseline was defined as the time when cases were diagnosed with both DM and AD in the NDR, and for matched controls, the time of NDR registration. Standardised mean difference (SMD) was used to estimate imbalances between the two groups with respect to the baseline variables. Imbalance was defined as an absolute SMD value >20%.
In the matching procedure, DM controls were matched 5:1, without replacement, to the cases based on the following variables: sex (male/female); DM type (1/2); year of birth (1902-1934, 1935-1943, 1944-1952 and 1953-) ; duration in years defined as the time from diagnosis of DM to AD diagnosis for cases and DM Table 1 Baseline demographics and measurements in patients with diabetes mellitus and Addison's disease and their matched controls with diabetes mellitus. Data are presented as n (%), mean (s.d.), or median (IQR) as appropriate for the whole study population (All) and patients with T1DM and T2DM respectively. Standardised mean difference between the diabetes mellitus and Addison's disease (DM and AD) and DM control groups (shown in the last column when relevant) is a measure of size effect, with imbalance between the groups defined as an absolute value >20%. duration until inclusion for controls (categorised as 0-3, 3-8, 8-14, 14-); and calendar year of DM and AD diagnosis for cases and year of registration in the NDR for controls (1996-2006, 2007-2009, 2010-2011, 2012) .
A Cox proportional hazards model was used to evaluate the mortality of cases compared with matched controls. Factors included in the model were year of DM diagnosis, year of inclusion in the study, the duration between these two dates, sex and the two groups of patients (DM and AD vs DM). Type of DM was used as a stratification factor due to the different shape of the hazard functions for patients with T1DM and T2DM Table 2 Medical history and co-morbidity in the 226 patients with diabetes mellitus and Addison's disease and their 1129 matched controls with diabetes mellitus. Data are presented as n (%) for the whole study population (All) and patients with T1DM and T2DM respectively. Standardised mean difference between the diabetes mellitus and Addison's disease (DM and AD) and DM control groups is a measure of size effect, with imbalance between the groups defined as an absolute value >20%. respectively. The relative risk of mortality of DM and AD vs DM, as well as T1DM and AD vs T1DM and T2DM and AD vs T2DM, were estimated by hazard ratios (HR) and their corresponding 95% confidence intervals (CIs). Survival curves were determined for matched data using the Kaplan-Meier method.
Results
Baseline
We identified 630 patients with DM who then developed AD or were registered with both diagnoses at the same time in the Swedish National Inpatient Register between 1 January 1988 and 31 December 2012 ( Fig. 1 ). Among these, 296 patients were registered after 1 January 1996, and we studied 226 of them who were also registered in the NDR. The 226 patients with DM and AD were matched to 1129 patients with DM in the NDR dataset containing 530 615 eligible patients. The median follow-up time of the patients was 5.9 years (IQR: 2.7-8.6), and the total study follow-up time was 8290 patient-years. For both groups combined (n = 1355), 887 patients (65%) had T1DM and 636 (47%) were female (Table 1) . Patients with T1DM were diagnosed with AD at a mean age of 43. Table 1 ). The proportion of DM complications at baseline (retinopathy, neuropathy and multiple DM complications) was higher in cases than that in controls. In contrast, the proportion of DM nephropathy and angiopathy did not differ among the two groups ( Table 2 ). The two patient groups did not differ in terms of medical history of hypertension, coronary heart disease including acute myocardial infarction, congestive heart failure, stroke and cancer. Medical history of infections requiring inpatient admission to hospital was increased in the DM and AD group compared with the DM controls (SMD = 45.7).
Mortality
The observed number of deaths was 64 in the 226 cases (28%) and 112 deaths in the 1129 controls (10%) ( Table 3 ). The adjusted relative risk increase (HR) in overall mortality of the DM and AD group was therefore 3.89 (95% CI: 2.84-5.32) compared with the DM controls (Fig. 2) . The adjusted relative risk increase in overall mortality was 4.28 (95% CI: 2.59-6.95) for patients with T1DM and AD, and 3.81 (95% CI: 2.52-5.75) for those with T2DM and AD compared with controls.
Cause-specific mortality
There were differences in the main causes of death between patients with DM and AD and patients with only DM (Fig. 3) . The most common main cause of death was cardiovascular disease in both groups, whereas deaths from DM complications, infections and unknown causes were more frequent among patients with DM and AD. Death from cancer was more frequent among patients with only DM.
Independent analysis of the Swedish National Inpatient Register cohort
In a separate mortality analysis, we matched the 630 patients with both DM and AD identified in the Swedish National Inpatient Register with 3138 controls with DM in NDR. Mean (s.d.) age at baseline was 57.2 (19.3) years for the cases and 58.8 (16.9) years for the controls. Median (IQR) DM duration was 1.2 (0-6) and 4 (2-7) years for cases and controls respectively. In the group of patients with DM and AD, 53.7% were female and 37.8% had T1DM, and in controls, 53.6% were female and 37.9% had T1DM. The observed number of deaths was 386 in the 630 cases (61%) ( Table 3) , and the adjusted relative risk increase in overall mortality in these patients was 6.62 (95% CI: 5.80-7.55) compared with their controls (Fig. 2 ).
Discussion
This nationwide study of patients with DM and AD in Sweden showed a near 4-fold increased risk of all-cause mortality compared with matched controls with DM. The most common cause of death in patients with DM and AD was cardiovascular disease, but death due to DM complications, infections or unknown causes was more common than that in patients with DM alone. At inclusion, degree of co-morbidities and glycaemic control did not differ markedly between patients with DM and AD and their controls, suggesting an impact of AD on the excess mortality.
Patients with DM have an increased mortality rate. Higher HbA1c in both T1DM and T2DM patients, and young age in T2DM patients are related to higher mortality (5, 21) . In addition, nephropathy is a serious co-morbidity increasing the risk of death in patients with DM (5, 21) . The most common diabetes complications in T1DM patients are microvascular (5, 22) , especially in those with long DM duration, whereas in T2DM patients, the most common diabetes complications are macrovascular (21) . In this study, we demonstrated that AD, as another DM co-morbidity, increased the overall risk of death in patients with DM.
A possible explanation for these deleterious effects of AD on mortality rate in patients with DM is the counter-balancing metabolic effects of insulin and cortisol, the main treatments for DM and AD respectively. Although treatment for DM addresses insulin resistance, enhancement of insulin secretion, or insulin replacement, treatment of AD means replacement therapy with glucocorticoids (mainly hydrocortisone). Glucocorticoids, as the name implies, stimulate glycogen deposition and increase hepatic glucose output and inhibit glucose uptake and utilisation in peripheral tissues, leading to insulin resistance and increased plasma glucose levels (23, 24) . This is why patients with T1DM present with reduced insulin requirement when they develop severe glucocorticoid deficiency due to AD (25) and why the risk of T2DM is increased in patients treated with pharmacological doses of glucocorticoids (26) . The doses of glucocorticoids used for replacement should be sufficient to prevent adrenal crisis but not too high to induce side effects, such as obesity, hypertension and DM (27, 28, 29) . Also, in patients with insulin-treated DM, the timing of the hydrocortisone dose in relation to the intake of meals and administration of insulin is of importance due to the short half-life of hydrocortisone. The main cause of death was cardiovascular diseases in both patients with DM with and without AD. Patients with DM and AD, however, died more frequently from complications related to DM, infections (including sepsis) and unknown causes. The increased rate of death from DM-related complications might be due to the higher proportion of almost all DM complications at baseline in patients with DM and AD. The explanation for this is unclear, but may be related to the fact that management of DM may be more difficult if the intrinsic regulation of cortisol secretion is impaired, which is likely to occur well in advance of the actual diagnosis of AD. Another explanation might be that patients with uncomplicated DM are treated by general practitioners, whereas DM patients with complications and AD are referred to specialists.
Patients with autoimmune diseases have an increased risk of cancer (30) and two previous Swedish studies in patients with AD and patients with autoimmune polyendocrine syndrome type 2 have shown increased death from cancer (10, 11) . Our data show reduced cancer mortality (as the main cause of death) in patients with DM and AD compared with patients with DM suggesting that AD or its treatment with glucocorticoids may modify the increased risk of cancer death among patients with DM.
Patients with AD are at risk of developing adrenal crisis, a life-threatening condition, if not rapidly treated with parenteral glucocorticoids and saline infusion. Therefore, patients with AD are taught to increase the dose of glucocorticoids in the event of infections or other physical and mental stress events to prevent a crisis. Previous studies have shown increased risk of adrenal crisis among patients with both T1DM and AD (13, 20, 31) . This study supports these previous observations by showing higher mortality from infections and unknown cause that may be explained by untreated or inadequately treated adrenal crisis, severe hypoglycaemia or their combination. These data indicate that patients with DM and AD need targeted education for managing both their DM and AD during an infection or other stressful events.
Data from the larger cohort generated from the Swedish National Inpatient Register were analysed as an independent study of the more selected cohort from the NDR. This analysis confirmed our primary analysis of excess mortality among patients with DM and AD and also suggested that the primary analysis did not overestimate the risk of death. The Kaplan-Meier probability curve in patients with DM and AD in the Inpatient Register had a steeper inclination during the first few years after AD was diagnosed in contrast to the probability curve for patients with DM and AD in our primary cohort. This is in agreement with previous findings showing that AD patients are at increased risk of death close to the time of diagnosis (10) .
This study has several strengths. First, a detailed description of the patients at baseline was possible from the NDR, which has a high nationwide coverage in Sweden. Second, our search criteria for AD in the Swedish National Inpatient Register have been validated in a previous study (10) . Finally, most of the reported main causes of death have been previously validated and shown to have a high reliability (18) .
One of the limitations of this study is the missing data around the period of the AD diagnosis in the NDR that made us define baseline as the data registered 1 year before the diagnosis and up to 2 weeks after the diagnosis. However, support for this decision is that AD emerges by a gradual destruction of the adrenal cortex before overt cortisol deficiency develops. Another limitation is that the registries used in this study have no information on patients' glucocorticoid replacement regimen.
In conclusion, this nationwide study shows that DM patients with AD have a substantially increased risk of death compared with closely matched patients with DM. The disease-specific mortality in patients with both DM and AD is increased for infections and unknown causes, suggesting that death due to adrenal crisis is a contributing factor. As adrenal crisis can be prevented by an adequate rescue regimen, this study highly alerts the risk of premature death from infections and other stressrelated events when patients with both DM and AD are not treated properly. Better patient education as well as a combined effort between physicians treating DM and those treating AD should be directed at improving the care of this patient group with a complex metabolic disease who, otherwise, have a very poor outcome as shown in this study.
